Labcorp Expands Automated Clinical Trial Kit Production Line at European Operations Center
BURLINGTON, NC–(BUSINESS WIRE)–Labcorp® (NYSE: LH), a leading global life sciences company, today announced the expansion of its automated clinical trial kit production line in Mechelen, Belgium. Once completed, the expansion will allow clinical trial test kits to be carried out in Mechelen for more than 70 countries across Europe, the Middle East and Africa (EMEA). This is an increase from 27 countries in 2021. The company’s industry-leading central laboratory services unit is part of Labcorp Drug Development.
“This additional capacity, a key part of our strategy for global growth and expansion, meets our customers’ needs for faster and more convenient testing and clinical trial delivery in the EMEA region,” said Jonathan. DiVincenzo, president of the Clinical Trial Testing Solutions group at Labcorp Drug Development. “The strengthening of our capabilities in Mechelen means that investigators will benefit from greater flexibility in order times and better regional turnaround times.”
The expanded automated line is housed in Labcorp Drug Development’s European Operations Center, a multi-purpose facility responsible for kit production as well as study logistics and support and dry ice production and distribution. Since opening in March 2021, this site has produced more than 1.1 million clinical research test kits across Europe in support of studies in oncology, diabetes, kidney disease and autoimmune diseases . Kit production follows the same global standard operating procedures in Europe and the United States, so sponsors and researchers will continue to receive the state-of-the-art sample collection kits they already associate with central laboratory services from Labcorp, wherever they are produced.
“Finding innovative ways to help our pharmaceutical and biotech customers quickly and safely deliver transformational therapies to patients who need them is critical,” said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. “The European Operations Center expands the capability of Labcorp Central Laboratory Services and supports the company’s future business growth. It builds on our business continuity infrastructure, providing additional flexibility in the event of disruptions or unexpected increases in demand. »
The expansion of the Mechelen facility follows recent expansions of Labcorp Drug Development’s central laboratories in Geneva, Switzerland, Los Angeles and Singapore, providing increased support for global clinical trials.
Labcorp is a leading global life sciences company that provides vital information to help physicians, hospitals, pharmaceutical companies, researchers and patients make informed decisions with confidence. Through our unparalleled diagnostic and drug development capabilities, we deliver insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve customers in over 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in fiscal 2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.